Trial Profile
A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects 18 Years of Age With Perennial Allergic Rhinitis (PAR)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary) ; Mometasone
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 22 Aug 2007 Status changed from recruiting to completed.
- 24 Dec 2005 New trial record.